🔗 Permalink

Inventor profile of:

Jonathan Moss

City:

Chicago, Illinois

Country:

United States

Published Applications:

Last publication date:

2025-06-12

Top Assignees for applications by Jonathan Moss

The entities that hold a legal rights for patent applications filed by inventor Moss Jonathan:

THE UNIVERSITY OF CHICAGO 16 Chicago, IL United States
Salix Pharmaceuticals, Inc. 3 Bridgewater, NJ United States
UNIVERSITY OF CHICAGO 1 CHICAGO, IL United States
Salix Pharmaceuticals, Inc. 1 Raleigh, NC United States

Recent patent applications by Moss Jonathan

Jonathan Moss from Chicago, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-12

US20250186423A1

Human necessities

METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST

#2 | 2023-06-15

US20230181571A1

Human necessities

USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION

#3 | 2021-05-20

US20210145825A1

Human necessities

USE OF OPIOID ANTAGONISTS

#4 | 2021-04-29

US20210121456A1

Human necessities

USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION

#5 | 2020-05-28

US20200163958A1

Human necessities

USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION

#6 | 2018-01-11

US20180008594A1

Human necessities

USE OF OPIOID ANTAGONISTS

#7 | 2017-09-14

US20170258909A1

Human necessities

USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION

#8 | 2017-09-07

US20170252336A1

Human necessities

USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION

#9 | 2017-07-20

US20170202832A1

Human necessities

USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION

#10 | 2017-03-09

US20170065581A1

Human necessities

Treatment with opioid antagonists and mTOR inhibitors

#11 | 2014-10-30

US20140323426A1

Human necessities

Use of opioid antagonists to attenuate endothelial cell proliferation and migration

#12 | 2014-06-12

US20140163059A1

Human necessities

Treatment with opioid antagonists and mTOR inhibitors

#13 | 2014-05-22

US20140142133A1

Human necessities

MODULATION OF CELL BARRIER DYSFUNCTION

#14 | 2014-03-06

US20140066467A1

Human necessities

Use of opioid antagonists to attenuate endothelial cell proliferation and migration

#15 | 2014-01-09

US20140011831A1

Human necessities

Use of opioid antagonists

#16 | 2012-12-13

US20120316190A1

Human necessities

Modulation of Cell Barrier Dysfunction

#17 | 2012-11-01

US20120277260A1

Human necessities

USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS

#18 | 2012-07-26

US20120190702A1

Human necessities

USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS

#19 | 2011-01-27

US20110021551A1

Human necessities

Treatment with opioid antagonists and mTOR inhibitors

#20 | 2010-11-11

US20100286059A1

Human necessities

Use of opioid antagonists

#21 | 2010-04-08

US20100087472A1

Human necessities

USE OF METHYLNALTREXONE AND RELATED COMPOUND TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS

#22 | 2009-12-17

US20090312359A1

Human necessities

USE OF METHYLNALTREXONE AND RELATED COMPOUNDS FOR TREATMENT OF GASTROINTESTINAL DYSFUNCTION INDUCED BY ENDOGENOUS OPIOIDS

#23 | 2008-11-06

US20080274119A1

Human necessities

Use of opioid antagonists to attenuate endothelial cell proliferation and migration

#24 | 2008-08-14

US20080194611A1

Human necessities

Modulation of Cell Barrier Dysfunction

#25 | 2006-11-16

US20060258696A1

Human necessities

Use of opioid antagonists to attenuate endothelial cell proliferation and migration

#26 | 2005-03-03

US20050048117A1

Human necessities

Use of methylnaltrexone and related compounds

#27 | 2005-01-20

US20050011468A1

Human necessities

Use of methylnaltrexone in treating gastrointestinal dysfunction in equines

InventorID:

606515 ⎘